Table 4 Outcome by mutation types and... | American Society of Hematology

Table 4

Outcome by mutation types and disease phase

Phase/mutation status before second TKI	N	2-year, %
Phase/mutation status before second TKI	N	EFS	OS
CP
None	29	63	96
Mutated low IC₅₀	15	78	100
Mutated intermediate IC₅₀	8	22	70
Mutated high IC₅₀	4	0	75
Mutated unknown IC₅₀	3	67	100
P*		<.001	.03
AP
None	30	27	49
Mutated low IC₅₀	21	9	60
Mutated intermediate IC₅₀	10	11	42
Mutated high IC₅₀	4	0	50
Mutated unknown IC₅₀	6	84	80
P*		.3	.37
BP
None	24	23	29
Mutated low IC₅₀	6	20	14
Mutated intermediate IC₅₀	7	0	14
Mutated high IC₅₀	1	0	0
Mutated unknown IC₅₀	1	0	0
P*		.7	.17

Phase/mutation status before second TKI	N	2-year, %
Phase/mutation status before second TKI	N	EFS	OS
CP
None	29	63	96
Mutated low IC₅₀	15	78	100
Mutated intermediate IC₅₀	8	22	70
Mutated high IC₅₀	4	0	75
Mutated unknown IC₅₀	3	67	100
P*		<.001	.03
AP
None	30	27	49
Mutated low IC₅₀	21	9	60
Mutated intermediate IC₅₀	10	11	42
Mutated high IC₅₀	4	0	50
Mutated unknown IC₅₀	6	84	80
P*		.3	.37
BP
None	24	23	29
Mutated low IC₅₀	6	20	14
Mutated intermediate IC₅₀	7	0	14
Mutated high IC₅₀	1	0	0
Mutated unknown IC₅₀	1	0	0
P*		.7	.17

Comparing low versus intermediate mutation classes.